PSYC Interviews Chief Architects and Petitioners of Oregon’s Psilocybin Therapy Initiative
- Tech pulls Nasdaq, S&P 500 down as Treasury yields rise
- Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Oil up on tight supply, Brent crude nears $80 a barrel
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
LAS VEGAS, July 21, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce the release of a special edition of its Microdose Monthly newsletter featuring an exclusive interview conducted by PSYC CEO, David Flores, and long-time psilocybin therapy advocates and Chief Petitioners of Initiative Petition 34 (“IP 34”) in the state of Oregon, Tom and Sheri Eckert.
Distributed this morning to Microdose Monthly subscribers, and now live on the Psychedelic Spotlight website under Spotlight Originals, the interview highlights the recent accomplishment of the IP 34 campaign team, guided, and led by chief architects, Tom and Sheri Eckert, in helping to secure the nearly 165,000 signatures required to place the initiative on the ballot in Oregon this November and providing Oregonians with the opportunity to potentially green light a state licensed and regulated psilocybin therapy program within the state.
According to data provided by Mental Health America, Oregon is currently ranked as one of the worst/bottom states in the U.S. in terms of its prevalence of mental health illnesses and disorders amongst its residents in addition to significantly lower rates of access to care when compared to other states. Such conditions, compounded by the recent COVID-19 pandemic, have created a significant mental health epidemic within the state and particularly for those struggling with a variety of illnesses and disorders such as depression, anxiety, and addiction. Based on encouraging data from research and studies performed by leading medical research institutions such as Johns Hopkins, UCLA, and NYU, Psilocybin therapy through IP 34 aims to provide Oregonians with a much needed alternative to conventional, and mostly pharma-based drugs, whereby placing more emphasis on treatment over management.
“I would first like to extend my sincerest gratitude and congratulations to Tom and Sheri Eckert for their tireless efforts, leadership, and dedication that have contributed to IP 34 earning a very important spot on the November ballot in Oregon,” said Global Trac Solutions, Inc. CEO, David Flores. “This represents a potentially exciting and critical step forward for the thousands of Oregonians struggling everyday with a variety of debilitating mental health illnesses and disorders in terms of laying the groundwork for expanded treatment options highlighted by a licensed and regulated psilocybin therapy program. In my opinion, this also represents an especially significant step forward for the psychedelic reform movement and industry as a whole and demonstrates the tangible momentum it is continuing to gain. And as this momentum continues to pick up traction, I look forward to maximizing the use of our Psychedelic Spotlight (www.psychedelicspotlight.com)and Microdose Monthly platforms to showcase many other leaders within this space who are contributing to its growth and emergence as a legitimate and full-fledged industry.”
PSYC encourages those interested in learning more about IP 34, or contributing to the initiative, to visit the campaigns primary website at: https://yesonip34.org/
About Global Trac Solutions, Inc. (OTC Pink: PSYC)
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
- CGG: Sercel Awarded Major Seismic Equipment Contract in North Africa
- WISeKey Reports H1 2021 Results
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!